topSkip to main content

Menu, Secondary

Menu Trigger

Menu

National Institutes of Health

Biomedical research funded by the National Institutes of Health (NIH) and performed at research universities helps assure U.S. leadership in the life sciences revolution of the 21st Century. Putting NIH on a sustained pathway to restore its purchasing power after a decade worth of loss to inflation and budget cuts is critical to sustaining the extraordinary progress in the improvement of human health of the past decades. Investment in NIH will continue to create jobs and strengthen the workforce, improve the lives—and quality of life—of millions of current and future patients, and help assure continuing U.S. economic and national security.

Sustained investment in biotechnology and genomics is crucial to the development of novel therapies for diseases, including: cancer, Alzheimer's, autism, and diabetes. The NIH also responds rapidly to public health emergencies and in support of biodefense, such as in the case of Ebola, Zika, and COVID-19.

 

Groups Urge congress appropriators not to lower NIH salary cap.
Response to Request for Information (RFI): Input into the Deliberations of the Advisory Committee to the NIH Director Working Group on the Future Biomedical Research Workforce Notice Number: NOT-OD-11-106 October 7, 2011
AAU and APLU, support the proposal to establish a new National Center for Advancing Translational Science (NCATS) and subsequent elimination of the National Center for Research Resources (NCRR).
AAU’s views on the Draft National Institutes of Health Guidelines for Human Stem Cell Research of April 23, 2009.
COGR, AAU and their member institutions appreciate the opportunity to provide comments on Draft HHS Gene Patent Report.
Comments on NIH response to Congress' request for analysis of the public interest in securing an appropriate return on the nation's investment in basic research.